The molecular features defining this new tumor entity include TERT mutation, EGFR amplification, or a combination of whole chromosome 7 gain and whole chromosome 10 loss.12 However, because grade II-III astrocytomas were not uniformly treated as aggressively as GBM in the past, additional clinical data should validate that molecular GBM (mGBM) has comparable clinical outcomes to hGBM after modern chemoradiotherapy. This evidence concerns the gene TERT and astrocytoma (excluding glioblastoma).